Global Drug Eluting Balloons (DEB) Market Strategic Research Report

Scope of the Report

The global Drug Eluting Balloons (DEB) market size is predicted to grow from US$ 1,487 million in 2025 to US$ 3,521 million in 2032; it is expected to grow at a CAGR of 13.0% from 2026 to 2032.

A drug-eluting balloon is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon. This is done to restore luminal vascularity in order to treat atherosclerosis, in-stent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object. The balloon technology relies on the concept of targeted drug delivery, which helps in the rapid healing of the vessel wall and prevents the proliferation of smooth muscle cells. Drug eluting balloon is a semi-compliant angioplasty balloon, coated with anti-proliferative medicine. The medicine is ejected to the vessel walls during the inflation of the balloon. The balloons are inflated through application of nominal pressure. In 2025, global drug-eluting balloon production reached approximately 1528 k units and price is 995 USD/Unit.The average gross profit margin of this product is 73%.

The Drug Eluting Balloons (DEB) market is being driven by the increasing global prevalence of cardiovascular diseases, particularly peripheral artery disease (PAD) and coronary artery disease (CAD). DEBs offer an effective alternative to traditional stents by delivering antiproliferative drugs directly to the vessel wall without leaving a permanent implant, reducing restenosis rates and improving long-term outcomes. Growing patient preference for minimally invasive procedures and shorter recovery times is also contributing to the adoption of DEBs. Furthermore, advancements in drug delivery technologies and increased clinical evidence supporting DEB efficacy are encouraging broader usage, especially among high-risk patients.

Despite their benefits, the DEB market faces several challenges. One key issue is the lack of uniform clinical guidelines and inconsistent results from clinical trials, which may hinder physician confidence and limit widespread adoption. Additionally, the high cost of DEBs compared to conventional balloons or bare-metal stents can be a barrier, particularly in emerging economies with limited healthcare budgets. Regulatory complexities and lengthy approval processes also pose significant hurdles for manufacturers. Furthermore, reimbursement policies vary across regions, creating market access disparities and limiting patient availability to these advanced therapies.

The DEB market is witnessing key trends such as the development of next-generation balloons with enhanced drug coatings and more efficient drug release profiles. There is growing interest in DEBs for treating new indications beyond peripheral and coronary artery disease, such as in-stent restenosis, small vessel disease, and arteriovenous fistula stenosis. Integration of imaging technologies, like intravascular ultrasound (IVUS) and optical coherence tomography (OCT), is also improving procedural outcomes. Additionally, strategic collaborations between medtech companies and research institutions are accelerating innovation, while increasing focus on personalized medicine is expected to drive customized DEB solutions in the near future.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Drug Eluting Balloons (DEB) market?

What factors are driving Drug Eluting Balloons (DEB) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Drug Eluting Balloons (DEB) market opportunities vary by end market size?

How does Drug Eluting Balloons (DEB) break out by Type, by Application?

This report presents a comprehensive overview of the global Drug Eluting Balloons (DEB) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Peripheral DEBs
• Coronary DEBs

Segment by Balloon Platform Mechanics

• Semi-/Compliant
• Non-compliant
• Other

Segment by Application

• Catheterization Laboratory
• Hospital
• Others

Segment by Application

• In-Stent Restenosi
• De Novo
• Small Vessel

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Drug Eluting Balloons (DEB) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in In-Stent Restenosi, De Novo, Small Vessel evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact